Clinical Trial

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-04-28; most recent amendment 2025-10-06.
Status change: Not Yet Recruiting → Recruiting 2020-09-22
Trial Details
NCT Number NCT04370587
Lead Sponsor ImmVira Pharma Co. Ltd
Conditions Solid Tumor, Melanoma, HNSCC, Sarcoma, Squamous Cell Carcinoma, NSCLC
Enrollment 30 participants
Start Date 2020-09-17
Primary Completion 2026-09-22 (estimated)
Study Completion 2027-01-10 (estimated)
Updated on ClinicalTrials.gov 2025-10-08